EGFR
Gli inibitori del recettore del fattore di crescita epidermico (EGFR) sono composti che bloccano la segnalazione dell'EGFR, un recettore spesso sovraespresso in vari tipi di cancro e che svolge un ruolo cruciale nell'angiogenesi. Gli inibitori dell'EGFR sono utilizzati per prevenire la crescita tumorale e le metastasi interrompendo le vie che promuovono la formazione di vasi sanguigni nei tumori. Questi inibitori sono ampiamente utilizzati nella ricerca e nella terapia del cancro. Presso CymitQuimica, offriamo una vasta selezione di inibitori dell'EGFR di alta qualità per supportare la tua ricerca in oncologia e angiogenesi.
Trovati 586 prodotti di "EGFR"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Z118332870
CAS:Z118332870 is a potent inhibitor of EGFR and BRD4.Formula:C18H18FN3O3Colore e forma:SolidPeso molecolare:343.35BPIQ-II (hydrochloride)
CAS:BPIQ-II, a selective EGFR inhibitor with an IC50 of 8 pM, targets ATP sites and halts EGF signals inside cells.Formula:C15H11BrClN5Colore e forma:SolidPeso molecolare:376.64PF-6422899
CAS:PF-6422899 irreversibly inhibits EGFR kinase activity by binding covalently to active-site cysteine residues in the ATP binding pocket of EGFR.Formula:C20H14ClFN4O2Colore e forma:SolidPeso molecolare:396.8MJ04
CAS:MJ04 is a selective inhibitor of Janus Kinase 3 (JAK3) with an IC50 of 2.03 nM. It hinders T cell differentiation and suppresses pro-inflammatory cytokines in macrophages induced by Lipopolysaccharides. In mice, MJ04 exhibits favorable pharmacokinetic properties and promotes hair growth in a DHT-induced alopecia model in athymic mice, without notable toxicity (LD50>2 g/kg).Formula:C20H16FN5Colore e forma:SolidPeso molecolare:345.37PF-06672131
CAS:PF-06672131 is a selective EGFR kinase inhibitor.Formula:C23H21ClFN5O2Colore e forma:SolidPeso molecolare:453.9UNC-CA359
CAS:UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.Formula:C18H14ClN3O2Colore e forma:SolidPeso molecolare:339.78EAI001
CAS:EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.Formula:C19H15N3O2SPurezza:99.94%Colore e forma:SolidPeso molecolare:349.41RG 14467
CAS:RG 14467 is an antagonist of epidermal growth factor-urogastrone.Formula:C14H14N2O3Colore e forma:SolidPeso molecolare:258.27CAY10717
CAS:CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.Formula:C29H25F3N6O3Colore e forma:SolidPeso molecolare:562.54RG 14921
CAS:RG 14921 is a pyridone analog of erbstatin, epidermal growth factor (EGF) receptor tyrosine kinase, and cAMP-dependent kinase.Formula:C11H9NO3Colore e forma:SolidPeso molecolare:203.19AFN941
CAS:AFN941 is a staurosporine analog, acting as a Jak3-specific inhibitor.Formula:C28H30N4O3Colore e forma:SolidPeso molecolare:470.56EGFR/HER2-IN-9
CAS:EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFRFormula:C25H25ClFN5O4Colore e forma:SolidPeso molecolare:513.95EGFR/C797S-IN-1
CAS:EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.Formula:C28H30N4O3Colore e forma:SolidPeso molecolare:470.56HKI-357 dimaleate
CAS:HKI-357 dimaleate is an irreversible dual inhibitor of EGFR and ERBB2. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.Formula:C39H37ClFN5O11Colore e forma:SolidPeso molecolare:806.2EGFR-IN-63
CAS:EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).Formula:C20H12BrN5SColore e forma:SolidPeso molecolare:434.31EGFR T790M/L858R-IN-5
CAS:EGFR T790M/L858R-IN-5 (example 52) functions as a potent EGFR T790M/L858R inhibitor, demonstrating a 92.9% inhibition rate at a concentration of 0.05 μM [1].Formula:C28H31N9OPeso molecolare:509.61BIBX 1382 Dihydrochloride
CAS:BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.Formula:C18H21Cl3FN7Colore e forma:SolidPeso molecolare:460.76EGFR-IN-69
CAS:EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.Formula:C31H37Cl2N7O3SColore e forma:SolidPeso molecolare:658.64(E/Z)-CP-724714
CAS:(E/Z)-CP-724714, comprising racemic mixtures of (E)-CP-724714 and (Z)-CP-724714 isomers, is a potent, selective, and orally active inhibitor of ErbB2 (HER2)[1].Formula:C27H27N5O3Purezza:98%Colore e forma:SolidPeso molecolare:469.54Tarlox-TKI
CAS:Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.Formula:C19H18BrClN6OPurezza:97.03%Colore e forma:SolidPeso molecolare:461.74EGFR-IN-54
CAS:EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.Formula:C17H14N4O4S3Colore e forma:SolidPeso molecolare:434.51EGFR-IN-21
CAS:EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.Formula:C36H44BrN10O2PColore e forma:SolidPeso molecolare:759.68EGFR-IN-67
CAS:EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].Formula:C18H17N3SColore e forma:SolidPeso molecolare:307.41EGFR-IN-73
CAS:EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].Formula:C19H17ClFN3O4Purezza:98%Colore e forma:SolidPeso molecolare:405.81Antiproliferative agent-34
CAS:Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.Formula:C27H27N7O5Purezza:98%Colore e forma:SolidPeso molecolare:529.55EGFR-IN-89
CAS:EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM againstFormula:C26H31FN8O2SPurezza:98%Colore e forma:SolidPeso molecolare:538.64(E/Z)-AG490
CAS:(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.Formula:C17H14N2O3Colore e forma:SolidPeso molecolare:294.3NSC81111
CAS:NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].Formula:C19H16O4Colore e forma:SolidPeso molecolare:308.33EGFR-IN-50
CAS:EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.Formula:C24H26BrN3O4S2Colore e forma:SolidPeso molecolare:564.51EGFR-IN-16
CAS:EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.
Formula:C16H11NO3Purezza:98%Colore e forma:SolidPeso molecolare:265.26EGFR-IN-75
EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.Formula:C10H6N6S2Colore e forma:SolidPeso molecolare:274.32EGFR-IN-53
CAS:EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].Formula:C14H13N3O2SColore e forma:SolidPeso molecolare:287.34EGFR-IN-28
CAS:EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .Formula:C31H39BrN10O3SColore e forma:SolidPeso molecolare:711.68BAY 2476568
CAS:BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).Formula:C24H27FN4O4Colore e forma:SolidPeso molecolare:454.49NSC114126
CAS:NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formula:C22H20O4Colore e forma:SolidPeso molecolare:348.39LDC0496
CAS:LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.Formula:C32H35N5O3Colore e forma:SolidPeso molecolare:537.65Lavendustin C6
CAS:Lavendustin C6 is a effective tyrosine kinase inhibitor.Formula:C20H25NO5Colore e forma:SolidPeso molecolare:359.42PDZ1i
CAS:PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.Formula:C28H26N8O4Colore e forma:SolidPeso molecolare:538.56Nazartinib mesylate
CAS:Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).Formula:C27H35ClN6O5SPurezza:98%Colore e forma:SolidPeso molecolare:591.12Tyrphostin AG 112
CAS:Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.Formula:C13H8N4OPurezza:99.14%Colore e forma:SolidPeso molecolare:236.23DBPR112
CAS:DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.Formula:C32H31N5O3Purezza:99.25%Colore e forma:SolidPeso molecolare:533.62MS 39
CAS:MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.Formula:C55H71ClFN9O7SColore e forma:SolidPeso molecolare:1056.72Epertinib
CAS:Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).
Formula:C30H27ClFN5O3Purezza:98%Colore e forma:SolidPeso molecolare:560.02RTC-5
CAS:RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.Formula:C24H22ClF3N2O3SPurezza:98.14%Colore e forma:SolidPeso molecolare:510.96Ref: TM-T12777
2mg35,00€5mg52,00€10mg78,00€25mg149,00€50mg235,00€100mg376,00€200mg550,00€1mL*10mM (DMSO)55,00€SDZ281-977
CAS:SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.Formula:C18H20O5Purezza:99.64%Colore e forma:SolidPeso molecolare:316.35EGFR-IN-2
CAS:EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.Formula:C26H33N9O3SPurezza:98.52% - 99.79%Colore e forma:SolidPeso molecolare:551.66Gefitinib N-oxide
CAS:Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.Formula:C22H24ClFN4O4Purezza:98%Colore e forma:SolidPeso molecolare:462.9Nimotuzumab
CAS:Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).Purezza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:147.64 kDaBKI-1369
CAS:BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).Formula:C23H27N7OColore e forma:SolidPeso molecolare:417.51EGFR-IN-68
CAS:EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.Formula:C24H22N2OColore e forma:SolidPeso molecolare:354.44JBJ-04-125-02
CAS:JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.Formula:C29H26FN5O3SPurezza:98%Colore e forma:SolidPeso molecolare:543.61GW 583340 dihydrochloride
CAS:GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.
Formula:C28H27Cl3FN5O3S2Purezza:98.80%Colore e forma:SolidPeso molecolare:671.03Mutated EGFR-IN-3
CAS:Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.Formula:C31H29FN4O2Purezza:98%Colore e forma:SolidPeso molecolare:508.59EGFR-IN-64
CAS:EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.Formula:C20H21N3O3Colore e forma:SolidPeso molecolare:351.4Mutated EGFR-IN-2
CAS:Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.Formula:C29H35FN8O3Purezza:98%Colore e forma:SolidPeso molecolare:562.64JNJ28871063 hydrochloride
CAS:ErbB receptor family inhibitorFormula:C24H28Cl2N6O3Purezza:98%Colore e forma:SolidPeso molecolare:519.42EGFR-IN-5
CAS:EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.
Formula:C31H38FN9OPurezza:98.17%Colore e forma:SolidPeso molecolare:571.69EGFR mutant-IN-2
CAS:EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].Formula:C27H27F3N6O2SColore e forma:SolidPeso molecolare:556.6EMI48
CAS:EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].Formula:C21H20N2O3Colore e forma:SolidPeso molecolare:348.4EGFR-IN-39
CAS:EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.Formula:C24H25ClN6O3Colore e forma:SolidPeso molecolare:480.95EMI56
CAS:EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].Formula:C21H20N2O3Colore e forma:SolidPeso molecolare:348.4EGFR-IN-55
CAS:"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."Formula:C25H25Cl2N7O2Colore e forma:SolidPeso molecolare:526.42Selatinib
CAS:Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.Formula:C29H26ClFN4O3SPurezza:98.00%Colore e forma:SolidPeso molecolare:565.06EGFR-IN-49
CAS:EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.Formula:C22H15N5O2SColore e forma:SolidPeso molecolare:413.45Tyrphostin 51
CAS:Tyrphostin 51 is an effective inhibitor of EGFR kinase.Formula:C13H8N4O3Purezza:98%Colore e forma:SolidPeso molecolare:268.23EGA
CAS:EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.Formula:C16H16BrN3OPurezza:98% - 99.6%Colore e forma:SolidPeso molecolare:346.22DS21360717
CAS:DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.Formula:C21H23N7OPurezza:98%Colore e forma:SolidPeso molecolare:389.45EGFR-IN-31
CAS:EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)Formula:C32H36FN7O2Colore e forma:SolidPeso molecolare:569.67EGFR/HER2-IN-3
CAS:EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.Formula:C26H23N5O3Colore e forma:SolidPeso molecolare:453.49MS 154N
CAS:MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.Formula:C47H56ClFN8O8Colore e forma:SolidPeso molecolare:915.45Limertinib
CAS:Limertinib (ASK120067) is a EGFR tyrosine kinase inhibitor targeting EGFR T790M, applicable for the study of non-small cell lung cancer.
Formula:C29H32ClN7O2Purezza:97.44%Colore e forma:SolidPeso molecolare:546.06EGFR-IN-25
CAS:EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.Formula:C34H43N9O2Colore e forma:SolidPeso molecolare:609.76JBJ-09-063 hydrochloride
JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.Formula:C31H30ClFN4O3SColore e forma:SolidPeso molecolare:593.11PD 173955-Analog1
CAS:PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.Formula:C21H14Cl2N4O3Colore e forma:SolidPeso molecolare:441.27Cloperastine fendizoate
CAS:Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).Formula:C40H38ClNO5Purezza:99.97%Colore e forma:SolidPeso molecolare:648.19EMI1
CAS:EMI1 targets mutated EGFR in drug-resistant NSCLC research.Formula:C20H18N2O3Purezza:99.96%Colore e forma:SolidPeso molecolare:334.37Tyrphostin A25
CAS:Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.Formula:C10H6N2O3Purezza:98.98%Colore e forma:Yellow Green Powder /Off-White SolidPeso molecolare:202.17Rezivertinib
CAS:Rezivertinib (BPI-7711) is an EGFR inhibitor with antitumor activity and can be used to study central nervous system diseases.Formula:C27H30N6O3Purezza:99.26% - 99.98%Colore e forma:SolidPeso molecolare:486.57Ref: TM-T36644
1mg64,00€5mg137,00€10mg187,00€25mg344,00€50mg492,00€100mg707,00€200mg938,00€1mL*10mM (DMSO)44,00€PD 174265
CAS:PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.Formula:C17H15BrN4OPurezza:99.51%Colore e forma:SolidPeso molecolare:371.23A-935142
CAS:A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.Formula:C18H19F3N2O2Purezza:98.97% - 99.91%Colore e forma:SolidPeso molecolare:352.35LY 456236 hydrochloride
CAS:LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM.Formula:C16H16ClN3O2Purezza:99.95%Colore e forma:SolidPeso molecolare:317.77EGFR-IN-99
CAS:EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor for the study of non-small cell lung cancer (NSCLC).Formula:C25H22FN7O3Purezza:97.75%Colore e forma:SolidPeso molecolare:487.49PKI-166
CAS:PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.Formula:C20H18N4OPurezza:99.2%Colore e forma:SolidPeso molecolare:330.38Ref: TM-T16549
2mg39,00€5mg75,00€10mg111,00€25mg215,00€50mg358,00€100mg572,00€200mg767,00€1mL*10mM (DMSO)84,00€Epitinib succinate
CAS:Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.Formula:C28H32N6O6Purezza:98.02% - 99.79%Colore e forma:SolidPeso molecolare:548.59Ref: TM-T35914
1mg75,00€2mg97,00€5mg170,00€10mg271,00€25mg449,00€50mg615,00€100mg843,00€500mg1.691,00€Falnidamol
CAS:Falnidamol (BIBX 1382), an oral selective EGFR inhibitor, IC50 3 nM, weak on ErbB2 and others, anti-cancer pyrimido-pyrimidine.Formula:C18H19ClFN7Purezza:98.816%Colore e forma:SolidPeso molecolare:387.84Ref: TM-TQ0271
2mg39,00€5mg60,00€10mg96,00€25mg182,00€50mg318,00€100mg439,00€200mg612,00€1mL*10mM (DMSO)60,00€EGFR-IN-9
CAS:EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).Formula:C29H24N4O3Purezza:99.8%Colore e forma:SolidPeso molecolare:476.53JND3229
CAS:JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.Formula:C33H41ClN8O2Purezza:98.75%Colore e forma:SolidPeso molecolare:617.18HKI-357
CAS:HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.Formula:C31H29ClFN5O3Purezza:99.91%Colore e forma:SolidPeso molecolare:574.05Ref: TM-T11569
1mg62,00€2mgPrezzo su richiesta5mg125,00€10mg188,00€25mg373,00€50mg540,00€100mg787,00€200mg1.035,00€1mL*10mM (DMSO)159,00€EGFR-IN-30
CAS:EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.Formula:C28H33BrN7O2PColore e forma:SolidPeso molecolare:610.49EGFR mutant-IN-1
EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.Formula:C34H39ClFN7O2Purezza:98%Colore e forma:SolidPeso molecolare:632.17EGFR/CSC-IN-1
CAS:EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potentialFormula:C54H54Cl2FN7O7S2Purezza:98%Colore e forma:SolidPeso molecolare:1067.08EGFR-IN-29
CAS:EGFR-IN-29 is a potent EGFR inhibitor.Formula:C36H46BrN8O2PColore e forma:SolidPeso molecolare:733.68BEBT-109
CAS:BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.Formula:C27H32N8O3Purezza:97.26%Colore e forma:SolidPeso molecolare:516.62′-Thioadenosine
CAS:2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM againstFormula:C10H13N5O3SPurezza:98%Colore e forma:SolidPeso molecolare:283.31DZD1516
CAS:DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in bothFormula:C28H27F2N7O3Purezza:98%Colore e forma:SolidPeso molecolare:547.56JGK-068S
CAS:Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].Formula:C22H23BrFN5O2Purezza:98%Colore e forma:SolidPeso molecolare:488.35EGFR-IN-61
CAS:EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).Formula:C33H37ClN8O3Purezza:98%Colore e forma:SolidPeso molecolare:629.15EGFR-IN-85
CAS:EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFRFormula:C26H30N8O2Purezza:98%Colore e forma:SolidPeso molecolare:486.57Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Formula:C42H51N9O5Colore e forma:SolidPeso molecolare:761.91EGFR-IN-36
CAS:EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).Formula:C26H25ClN6O2Colore e forma:SolidPeso molecolare:488.97EGFR-IN-1
CAS:EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.
Formula:C28H30N6O4Purezza:98%Colore e forma:SolidPeso molecolare:514.58HER2-IN-5
CAS:HER2-IN-5 is an effective inhibitor of orally active HER-2.Formula:C27H33N7O3Colore e forma:SolidPeso molecolare:503.6Lifirafenib
CAS:Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinantFormula:C25H17F3N4O3Purezza:97.99% - 98%Colore e forma:SolidPeso molecolare:478.42Ref: TM-T22272
1mg34,00€5mg65,00€10mg92,00€25mg180,00€50mgPrezzo su richiesta100mgPrezzo su richiesta1mL*10mM (DMSO)94,00€BMS-599626 Hydrochloride
CAS:BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Formula:C27H28ClFN8O3Purezza:99.98%Colore e forma:SolidPeso molecolare:567.01EGFR-IN-33
CAS:EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).Formula:C26H25ClN6O2Colore e forma:SolidPeso molecolare:488.97EGFR-IN-71
CAS:EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.
Formula:C16H9ClIN3Colore e forma:SolidPeso molecolare:405.62EGFR/HER2-IN-11
CAS:EGFR/HER2-IN-11 (compound 20), an orally active dual inhibitor targeting human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), demonstrates IC50 values of 7.7 nM and 22 nM, respectively. This compound shows strong antitumor efficacy, specifically inhibiting the proliferation of BT-474 cancer cells with a GI50 of 601 nM [1].Formula:C23H21ClF3N5O2Colore e forma:SolidPeso molecolare:491.89Nazartinib S-enantiomer
CAS:Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.Formula:C26H31ClN6O2Purezza:98%Colore e forma:SolidPeso molecolare:495.02EGFR/HER2-IN-13
CAS:EGFR/HER2-IN-13 (Compd 38) serves as an inhibitor targeting mutant EGFR/HER2s that show resistance to existing drugs. It is primarily utilized in cancer research.Formula:C27H36N8O3Peso molecolare:520.63Simotinib
CAS:Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.Formula:C25H26ClFN4O4Purezza:99.7%Colore e forma:SolidPeso molecolare:500.95(Z)-RG-13022
CAS:(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].Formula:C16H14N2O2Colore e forma:SolidPeso molecolare:266.29EGFR-IN-32
CAS:EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Formula:C31H34N6O3Colore e forma:SolidPeso molecolare:538.64PAT-505
CAS:PAT-505 is an autologous epidermal growth factor inhibitor.Formula:C23H18ClF2N3O2SPurezza:98.84%Colore e forma:SolidPeso molecolare:473.92BGB-102
CAS:BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.Formula:C22H25BrN4O2Purezza:99.02%Colore e forma:SolidPeso molecolare:457.36MS 154
CAS:MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.Formula:C46H54ClFN8O8Colore e forma:SolidPeso molecolare:901.42EGFR-IN-74
EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.Formula:C32H28BrF3N6O4SColore e forma:SolidPeso molecolare:729.57BPIQ-I
CAS:BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.Formula:C16H12BrN5Colore e forma:SolidPeso molecolare:354.2PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Formula:C19H22ClN7O3Purezza:98%Colore e forma:SolidPeso molecolare:431.88EGFR/ErbB-2 inhibitor-1
CAS:EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.Formula:C23H15ClFN3OS2Purezza:98.93%Colore e forma:SolidPeso molecolare:467.97EGFR-IN-1 hydrochloride
CAS:EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Formula:C28H31ClN6O4Purezza:99.16%Colore e forma:SolidPeso molecolare:551.04Ref: TM-T11157L
1mg62,00€5mg142,00€10mg205,00€25mg319,00€50mg429,00€100mg587,00€200mg795,00€1mL*10mM (DMSO)190,00€EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purezza:98.64%Colore e forma:SolidPeso molecolare:499.61Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Formula:C24H25ClN4O5Purezza:99.81%Colore e forma:SolidPeso molecolare:484.93EGFR-IN-8
CAS:EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC
Formula:C32H23ClF3N7O4Purezza:99.51%Colore e forma:SolidPeso molecolare:662.02EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Formula:C12H14N4OS2Colore e forma:SolidPeso molecolare:294.4EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formula:C19H21N3O2SColore e forma:SolidPeso molecolare:355.45EGFR-IN-48
EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.Colore e forma:SolidEGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Formula:C33H28N6O3SColore e forma:SolidPeso molecolare:588.68HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Formula:C28H26F3N7O3Colore e forma:SolidPeso molecolare:565.55Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formula:C10H8N2OColore e forma:SolidPeso molecolare:172.183EGFR-IN-126
CAS:EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.Formula:C28H28BrFN4O3Colore e forma:SolidPeso molecolare:567.45JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formula:C27H20N4O2SPurezza:98%Colore e forma:SolidPeso molecolare:464.54EGFR-IN-139
CAS:EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formula:C27H25ClN2O4Colore e forma:SolidPeso molecolare:476.951ES-072
CAS:ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.Formula:C25H27F3N8O2Colore e forma:SolidPeso molecolare:528.53BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Formula:C29H33ClN8O4Colore e forma:SolidPeso molecolare:593.08EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formula:C27H19ClFN3OColore e forma:SolidPeso molecolare:455.91EGFR-IN-159
CAS:EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.
Formula:C21H23N3O5Colore e forma:SolidPeso molecolare:397.424EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Formula:C27H31ClN7O3PColore e forma:SolidPeso molecolare:568.01Neptinib
CAS:Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.Formula:C22H23ClFN5O2Colore e forma:SolidPeso molecolare:443.90EGFR Ligand-Linker Conjugates 1
CAS:EGFRLigand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising an EGFR ligand and a PROTAC linker, designed to recruit the E3 ligase. It is used in the synthesis of PROTACEGFRdegrader 3.Formula:C37H47N9O3Colore e forma:SolidPeso molecolare:665.83Tarloxotinib bromide
CAS:Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formula:C24H24Br2ClN9O3Purezza:99.52%Colore e forma:SolidPeso molecolare:681.77Ref: TM-T13088
1mg133,00€5mg268,00€10mg409,00€25mg670,00€50mg888,00€100mg1.243,00€1mL*10mM (DMSO)414,00€EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formula:C16H16N4O2SColore e forma:SolidPeso molecolare:328.39EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formula:C30H35FN6O3Colore e forma:SolidPeso molecolare:546.64JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formula:C31H29FN4O3SColore e forma:SolidPeso molecolare:556.65Andamertinib
CAS:Andamertinib is an EGFR inhibitor with antitumor activity.Formula:C31H36N8O3Colore e forma:SolidPeso molecolare:568.669EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formula:C26H28ClN3O4Colore e forma:SolidPeso molecolare:481.97HER2-IN-6
CAS:HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Formula:C26H32N8O3Colore e forma:SolidPeso molecolare:504.58Si306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formula:C25H26BrClN6OSColore e forma:SolidPeso molecolare:573.94EGFR-IN-23
CAS:EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Formula:C36H44BrN10O3PColore e forma:SolidPeso molecolare:775.68HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formula:C19H14BrF3N2OColore e forma:SolidPeso molecolare:423.23BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Formula:C18H15N3O2Colore e forma:SolidPeso molecolare:305.331EGFR-IN-125
CAS:EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).Formula:C30H26N8OColore e forma:SolidPeso molecolare:514.58EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formula:C14H11BrN4O2SColore e forma:SolidPeso molecolare:379.23NSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formula:C20H16O7Colore e forma:SolidPeso molecolare:368.34EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Formula:C31H30FN7OColore e forma:SolidPeso molecolare:535.61EGFR-IN-149
CAS:EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Formula:C16H15N3OSColore e forma:SolidPeso molecolare:297.375Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formula:C32H31ClN6O4Colore e forma:SolidPeso molecolare:599.08EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formula:C26H27ClN6O2Colore e forma:SolidPeso molecolare:490.98EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formula:C15H12N2O4Colore e forma:SolidPeso molecolare:284.27PROTAC Her3-binding moiety 2
CAS:PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.Formula:C25H25N7O2Colore e forma:SolidPeso molecolare:455.51EG31
CAS:EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formula:C30H13Br2N3O6Colore e forma:SolidPeso molecolare:671.25HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Colore e forma:SolidPeso molecolare:549.53HER2-IN-21
CAS:HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.
Formula:C20H18N4O3SColore e forma:SolidPeso molecolare:394.447EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formula:C13H13N5OColore e forma:SolidPeso molecolare:255.275EGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formula:C25H24ClN7O2Colore e forma:SolidPeso molecolare:489.96EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Colore e forma:SolidSORT1-IN-5
CAS:SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Formula:C19H31NO6SColore e forma:SolidPeso molecolare:401.52EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Colore e forma:SolidEGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formula:C25H24ClN7O2Colore e forma:SolidPeso molecolare:489.96Tesevatinib tosylate
CAS:Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Formula:C31H33Cl2FN4O5SColore e forma:SolidPeso molecolare:663.59EGFR-IN-132
CAS:EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Formula:C27H31N7O3Colore e forma:SolidPeso molecolare:501.58Tyrosine Protein Kinase Substrate
CAS:Tyrosine Protein Kinase Substrate is a polypeptide molecule with the sequence RRLIEDNEYTARG.Formula:C66H109N23O23Peso molecolare:1592.71LSD1/EGFR-IN-1
CAS:LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.
Formula:C21H20ClN3O4Colore e forma:SolidPeso molecolare:413.854D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formula:C25H26Cl2FN7O3Colore e forma:SolidPeso molecolare:562.42EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Formula:C27H25N3O6SColore e forma:SolidPeso molecolare:519.57HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Formula:C17H18BrN5O2SColore e forma:SolidPeso molecolare:436.33EGFR-IN-7
CAS:EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.
Formula:C32H41BrN9O2PPurezza:95.32% - 99.64%Colore e forma:SolidPeso molecolare:694.6Nimotuzumab (powder)
CAS:Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Colore e forma:LiquidImbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Colore e forma:Odour LiquidHMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Colore e forma:Odour LiquidTLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFormula:C16H15N5Colore e forma:Yellow SolidPeso molecolare:277.331Olmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormula:C26H26N6O2SPurezza:99.14%Colore e forma:SolidPeso molecolare:486.59Duligotuzumab
CAS:Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Purezza:95%Colore e forma:LiquidRef: TM-T80604
Prodotto fuori produzioneEGFR-IN-82
CAS:EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/
Formula:C32H41BrN9O2PPurezza:98%Colore e forma:SolidPeso molecolare:694.6Ref: TM-T78788
Prodotto fuori produzioneYK-029A
CAS:YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.
Formula:C27H32N8O2Purezza:98%Colore e forma:SolidPeso molecolare:500.6Ref: TM-T79461
Prodotto fuori produzioneEGFR-IN-123
CAS:EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.
Formula:C24H27F3N6OColore e forma:SolidPeso molecolare:472.51Ref: TM-T200485
Prodotto fuori produzioneEGFR-IN-122
CAS:EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.
Formula:C19H20N4O3Colore e forma:SolidPeso molecolare:352.39Ref: TM-T200157
Prodotto fuori produzione
